Latest Biotech News

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, seeking to expand its ophthalmology pipeline beyond its current Eylea franchise. The deal adds full rights to PER-001, a...

Roche agreed to acquire PathAI in a transaction valued at up to $1.05 billion to strengthen its digital pathology capabilities and expand AI-enabled diagnostic workflows. Roche will pay $750...

Odyssey Therapeutics raised $304 million through an upsized IPO and concurrent private placement, putting fresh capital behind its ulcerative colitis program and expanding its autoimmune pipeline....

ParcelBio secured $13 million in seed financing to develop its APEXm (Amplified and Prolonged EXpression mRNA) platform and advance an in vivo CAR T program for autoimmune disease. The round was...

Arrivent Biopharma received FDA IND clearance for ARR-002 (AV-P138-ADC), an antibody-drug conjugate aimed initially at ovarian and endometrial cancers, with broader potential across solid tumors....

Researchers unveiled a cell-free DNA fragmentomics approach that decodes tumor-linked nucleosomal patterns by analyzing the size distribution of circulating cfDNA fragments. The method links...

10x Genomics sued Element Biosciences, alleging that Element’s Aviti24 multiomic analysis platform infringes spatial technology patents licensed from Harvard University. The complaint, filed in...

Guardant Health reported Q1 2026 revenue growth of 48% year over year, driven by increases in both minimal residual disease (MRD) testing and broader oncology and screening activity. The company...

The FDA granted accelerated approval to Regeneron’s Otarmeni (lunsotogene parvec-cwha), described as the first gene therapy intended to restore neurosensory function in OTOF-related sensorineural...

Biogen and Eisai said the FDA delayed its decision on subcutaneous Leqembi, pushing the review date to August 24. The original decision timing was later this month, extending uncertainty for a...

Pierre Fabre and Atara Biotherapeutics said the FDA will reconsider Ebvallo (tabelecleucel/tab-cel) after the agency previously rejected the therapy using the same underlying single-arm evidence...

Roche agreed to acquire PathAI for up to $1.05 billion, aiming to accelerate use of AI in diagnostic workflows. Roche will pay $750 million upfront and up to $300 million in milestone-linked...

Angelini Pharma is buying Catalyst Pharmaceuticals for about $4.1 billion in cash, paying $31.50 per share. The all-cash offer represents a premium to Catalyst’s recent trading levels and is...

Researchers at the La Jolla Institute for Immunology (LJI) identified human monoclonal antibodies that neutralize measles virus by blocking viral entry through two essential surface proteins:...

Vyriad said it will showcase its G-Link modular CAR T delivery platform at the American Society of Gene & Cell Therapy (ASGCT) meeting in Boston. The company described G-Link as a plug-and-play...

ParcelBio raised $13 million in seed financing led by Breyer Capital, with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, and others. The company will use the...

Natera raised its 2026 revenue guidance after reporting a 39% year-over-year jump in Q1 revenue driven by growth in clinical oncology testing and women’s health volumes. The company reset its...

Alamar Biosciences became newly publicly traded after a $220 million IPO and reported a Q1 2026 revenue surge that nearly doubled year over year. The proteomics company posted $26.0 million in...

The US FDA agreed to reconsider approval of Atara Biotherapeutics and Pierre Fabre Pharmaceuticals’ off-the-shelf T-cell therapy Ebvallo (tabelecleucel/tab-cel) after a second meeting that walked...

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, adding PER-001 to its ophthalmology development pipeline. The deal includes a $300 million upfront payment and additional...